

gp130 mAb binders on Mouse atrial fibroblasts			
rmll11	Antibody Candidate	% of activated fibroblasts	Activated fibroblasts (norm.)
-	-	20.9%	1.00
24h	-	50.0%	2.39
24h	Industry Standard	22.3%	1.07
24h	CSP-3G9	22.7%	1.09
24h	CSP-4A7	44.4%	2.12
24h	CSP-7D8	46.6%	2.23
24h	CSP-8C6	21.7%	1.04

Figure 1A

gp130 mAb binders on Mouse atrial fibroblasts			
rmll11	Antibody Candidate	MMP2 concentration in the cell culture supernatants (ng)	MMP2 concentration (norm.)
-	-	33.1	1
24h	-	59.7	1.80447265
24h	Industry Standard	29.9	0.904502871
24h	CSP-3G9	36.9	1.115140526
24h	CSP-4A7	51.1	1.543668782
24h	CSP-7D8	37.4	1.130855243
24h	CSP-8C6	37.0	1.119371411

Figure 1B




Figure 2




Figure 3




Figure 4




Figure 5A




Figure 5B




Figure 5C




Figure 6A




Figure 6B




Figure 6C




Figure 6D




Figure 6E




Figure 6F




Figure 7A




Figure 7B




Figure 7C




Figure 7D




Figure 8A




Figure 8B




Figure 8C




Figure 8D




Figure 8E




Figure 8F




Figure 9A




Figure 9B




Figure 10A




Figure 10B




Figure 10C




Figure 10D




Figure 10E




Figure 10F




Figure 10G




Figure 10H




Figure 10I




Figure 10J





Figure 10J (continued)






Figure 11C



Figure 12A




Figure 12B




Figure 12C




Figure 12D




Figure 12E




Figure 12F




Figure 12G




Figure 12H




Figure 12I




Figure 12J



Figure 12K




Figure 12L




Figure 13A




Figure 13B




Figure 13C




Figure 13D




Figure 13E




Figure 13F




Figure 13G




Figure 13H




Figure 13I




Figure 13J




Figure 13K




Figure 13L




Figure 14A




Figure 14B

Hybridoma supernatants incubated on...											
...BOSC cells transfected with					...CHO cells transfected with						
Clone	pB1-GP130-hum.MC		non transfected cells (BOSC)		pB1-GP130-mur.MC	pB1-GP130-hum.ECD	pB1-GP130-mur.ECD	non transfected cells (CHO)			
	GMFI	%positive	GMFI	%positive	GMFI	%positive	GMFI	%positive	GMFI		
flow-cytometry (Attunes)											
Results of expansion (MS4) (30.12.2020)											
CSP-s-3G9	113598	112%	2504		13647	45%	22240	68%	28954	56%	322
CSP-s-4A7	108570	107%	2414		11415	38%	24669	76%	23451	45%	307
CSP-s-4D4	49767	49%	1456		2604	9%	18146	56%	5859	11%	294
CSP-s-7D8	126404	125%	2458		11255	37%	24996	77%	30064	58%	322
CSP-s-8C6	60340	60%	1545		6434	21%	13670	42%	20291	39%	298
positive control	101062	100%	3249		30253	100%	32589	100%	51728	100%	309
negative control	298	0%	232		425	1%	525	2%	434	1%	293

Figure 14C




Figure 14D




Figure 14E




Figure 15




Figure 16A




Figure 16B




Figure 16C




Figure 17A




Figure 17A (continued)




Figure 17A (continued)

Antibody	k_a (1/Ms)	k_d (1/s)	K_D (M)	Relative K_D	R_{MAX}	χ^2 (RU ²)
VH0/VL0	4.99E+05	2.53E-04	5.08E-10	1.00	89.7	0.326
VH0/CVL1	4.22E+05	2.60E-04	6.18E-10	1.22	94.2	0.427
CVH2/VL0	2.82E+05	1.77E-04	6.27E-10	1.23	87.5	0.416
CVH2/CVL1	2.60E+05	2.15E-04	8.26E-10	1.63	83.8	0.106
CVH2/CVL2	1.13E+05	1.69E-04	1.49E-09*	2.93	71.7	0.422
CVH2/CVL4	1.67E+05	1.30E-04	7.77E-10*	1.53	56.8	0.439
CVH2/GVL4	2.97E+05	3.34E-04	1.12E-09	2.20	93.3	0.147
CVH3/CVL1	1.75E+05	1.75E-04	9.99E-10*	1.97	66.3	0.407
CVH3/CVL2	3.02E+05	2.05E-04	6.79E-10*	1.34	12.2	0.0696
CVH3/CVL4	6.93E+04	3.25E-04	4.69E-09*	9.23	15.3	0.379
CVH3/GVL4	2.10E+05	3.52E-04	1.67E-09*	3.29	68.4	0.415
CVH4/CVL1	1.74E+05	2.62E-04	1.51E-09*	2.97	59.8	0.546
CVH4/CVL2	9.47E+04	3.12E-04	3.30E-09*	6.50	15.5	0.0271
CVH4/CVL4	4.85E+04	4.38E-04	9.04E-09*	17.80	28.5	0.47
CVH4/GVL4	1.68E+05	4.38E-04	2.61E-09*	5.14	71.4	0.369

Figure 17B




Figure 17C




Figure 17C (continued)




Figure 17C (continued)




Figure 17C (continued)

Antibody	k_a (1/Ms)	k_d (1/s)	K_D (M)	Relative K_D	R_{MAX}	χ^2 (RU ²)
VH0/VL0	5.65E+05	2.75E-04	4.87E-10	1.00	98.2	0.417
VH0/CVL1	4.82E+05	2.87E-04	5.96E-10	1.22	86.8	0.617
CVH2/VL0	2.78E+05	1.99E-04	7.14E-10	1.47	89	0.544
CVH2/CVL1	2.55E+05	1.99E-04	7.80E-10	1.60	82.4	0.122
CVH2/GVL3	2.88E+05	1.30E-04	4.51E-10	0.93	83.5	0.577
CVH2/GVL4	2.98E+05	3.59E-04	1.20E-09	2.46	78.3	0.518
CVH2.1/CVL1	1.38E+05	2.35E-04	1.70E-09*	3.49	71.8	0.0615
CVH2.1/GVL3	1.47E+05	1.58E-04	1.07E-09*	2.20	67.4	0.511
CVH2.1/GVL4	1.88E+05	4.11E-04	2.18E-09*	4.48	76	0.509
CVH2.2/CVL1	2.26E+05	1.88E-04	8.32E-10	1.71	86	0.594
CVH2.2/GVL3	2.47E+05	1.22E-04	4.93E-10	1.01	96.4	0.58
CVH2.2/GVL4	2.72E+05	3.35E-04	1.23E-09	2.53	83.5	0.126
CVH3/CVL1	1.25E+05	2.10E-04	1.68E-09*	3.45	71.9	0.589
CVH3/GVL3	1.34E+05	1.32E-04	9.86E-10*	2.02	67.2	0.557
CVH3/GVL4	1.81E+05	3.60E-04	1.99E-09*	4.09	59.3	0.622

Figure 17D




Figure 18A




Figure 18B




Figure 18C




Figure 19




Figure 19B




Figure 19C



Figure 20A




Figure 20B




Figure 20C




Figure 21A




Figure 21B




Figure 22A




Figure 22B




Figure 23





Figure 24A







Figure 24B








Figure 24G